CA3162280A1 - 4,5-dihydro-1h-pyrazolyl compounds as repication protein a (rpa)-dna interaction inhibitors - Google Patents
4,5-dihydro-1h-pyrazolyl compounds as repication protein a (rpa)-dna interaction inhibitorsInfo
- Publication number
- CA3162280A1 CA3162280A1 CA3162280A CA3162280A CA3162280A1 CA 3162280 A1 CA3162280 A1 CA 3162280A1 CA 3162280 A CA3162280 A CA 3162280A CA 3162280 A CA3162280 A CA 3162280A CA 3162280 A1 CA3162280 A1 CA 3162280A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- chloro
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946100P | 2019-12-10 | 2019-12-10 | |
| US62/946,100 | 2019-12-10 | ||
| PCT/US2020/064191 WO2021119242A1 (en) | 2019-12-10 | 2020-12-10 | Replication protein a (rpa)-dna interaction inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3162280A1 true CA3162280A1 (en) | 2021-06-17 |
Family
ID=76330773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3162280A Pending CA3162280A1 (en) | 2019-12-10 | 2020-12-10 | 4,5-dihydro-1h-pyrazolyl compounds as repication protein a (rpa)-dna interaction inhibitors |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12486246B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4073055B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7677646B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022011372A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3162280A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021119242A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017205503A1 (en) | 2016-05-24 | 2017-11-30 | Indiana University Research And Technology Corporation | Ku inhibitors and their use |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070196395A1 (en) | 2003-12-12 | 2007-08-23 | Mackerell Alexander | Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain |
| JP2008515992A (ja) * | 2004-10-13 | 2008-05-15 | ピーティーシー セラピューティクス，インコーポレーテッド | 体細胞変異に起因する疾患の阻止／治療用医薬を製造するための規定化合物の使用 |
| EP1905762A1 (en) | 2005-05-30 | 2008-04-02 | Genecare Research Institute Co., Ltd | Pyrazolone derivative |
| US20100055116A1 (en) | 2006-04-13 | 2010-03-04 | Liou Hsiou-Chi | Methods and Compositions for Targeting c-Rel |
| WO2008045663A2 (en) * | 2006-10-06 | 2008-04-17 | Kalypsys, Inc. | Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents |
| PT2139484E (pt) | 2007-04-10 | 2013-10-31 | Exelixis Inc | Métodos de tratamento de cancro usando inibidores piridopirimidinona de pi3k-alfa |
| US20100249165A1 (en) | 2007-06-08 | 2010-09-30 | University Of Copenhagen | Pdz domain modulators |
| WO2008157680A2 (en) | 2007-06-21 | 2008-12-24 | The Wistar Institute | Methods and compositions for modulating p300/cbp activity |
| ES2585157T3 (es) | 2007-09-27 | 2016-10-04 | Dow Agrosciences Llc | Proteínas de dedo de cinc de diseño que se dirigen a los genes de 5-enolpiruvil shikimato-3-fosfato sintasa |
| US8716283B2 (en) | 2007-11-07 | 2014-05-06 | University Of Massachusetts | Type III secretion inhibitors, analogs and uses thereof |
| WO2009146179A1 (en) | 2008-04-15 | 2009-12-03 | University Of Iowa Research Foundation | Zinc finger nuclease for the cftr gene and methods of use thereof |
| US9005670B2 (en) | 2010-01-05 | 2015-04-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| CA2825680C (en) * | 2010-02-05 | 2019-12-03 | Indiana University Research And Technology Corporation | Materials and method for inhibiting replication protein a and uses thereof |
| US8980955B2 (en) | 2010-09-17 | 2015-03-17 | Indiana University Research And Technology | Small molecule inhibitors of replication protein A that also act synergistically with cisplatin |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| KR102955556B1 (ko) | 2012-12-12 | 2026-04-22 | 더 브로드 인스티튜트, 인코퍼레이티드 | 서열 조작을 위한 crispr-cas 성분 시스템, 방법 및 조성물 |
| US10227610B2 (en) | 2013-02-25 | 2019-03-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
| EP3022304B1 (en) | 2013-07-19 | 2018-12-26 | Larix Biosciences LLC | Methods and compositions for producing double allele knock outs |
| US20150044772A1 (en) | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | Crispr/cas system-based novel fusion protein and its applications in genome editing |
| ITMI20131410A1 (it) | 2013-08-26 | 2015-02-27 | Univ Degli Studi Modena E Reggio Emilia | Composti e composizioni per l'uso nella inibizione dell' interazione lbc-rhoa |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US10774063B2 (en) * | 2014-11-13 | 2020-09-15 | Indiana University Research And Technology Corporation | Materials and method for inhibiting replication protein A and uses thereof |
| WO2017205503A1 (en) | 2016-05-24 | 2017-11-30 | Indiana University Research And Technology Corporation | Ku inhibitors and their use |
| CA3075734A1 (en) | 2017-09-19 | 2019-03-28 | Indiana University Research And Technology Corporation | Xpa inhibitor compounds and their use |
-
2020
- 2020-12-10 WO PCT/US2020/064191 patent/WO2021119242A1/en not_active Ceased
- 2020-12-10 EP EP20897908.8A patent/EP4073055B1/en active Active
- 2020-12-10 US US17/782,876 patent/US12486246B2/en active Active
- 2020-12-10 CA CA3162280A patent/CA3162280A1/en active Pending
- 2020-12-10 BR BR112022011372A patent/BR112022011372A2/pt unknown
- 2020-12-10 JP JP2022535116A patent/JP7677646B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP4073055B1 (en) | 2026-07-29 |
| US12486246B2 (en) | 2025-12-02 |
| EP4073055A1 (en) | 2022-10-19 |
| JP7677646B2 (ja) | 2025-05-15 |
| WO2021119242A1 (en) | 2021-06-17 |
| BR112022011372A2 (pt) | 2022-08-23 |
| US20230056729A1 (en) | 2023-02-23 |
| JP2023505690A (ja) | 2023-02-10 |
| EP4073055A4 (en) | 2024-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2253625B1 (en) | Pyridazinones, the preparation and the use thereof | |
| JP4405602B2 (ja) | ヒストン脱アセチル化酵素阻害剤 | |
| EP3438094A1 (en) | Selective c-kit kinase inhibitor | |
| AU2020225225A1 (en) | Solid forms of FXR agonists | |
| WO2017101803A1 (zh) | 一种新型egfr和alk激酶的双重抑制剂 | |
| KR20170053686A (ko) | Raf 키나제 억제제로서의 화합물 및 조성물 | |
| KR20130008557A (ko) | Ｃｄｋ4/6의 억제제로서의 중수소화 피롤로피리미딘 화합물 | |
| JP6821680B2 (ja) | １，３，４−チアジアゾール化合物およびがんの治療におけるその使用 | |
| JP2016503003A (ja) | ナンセンス突然変異抑制剤としてのピリミド［４，５−ｂ］キノリン−４，５（３ｈ，１０ｈ）−ジオン | |
| JP2023529570A (ja) | Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン | |
| WO2012073184A1 (en) | Quinolin-4 (1h) -one derivatives as inhibitors of phosphatidylinositol 3-kinases | |
| EP4069700B1 (en) | Macrocycles for use in treating disease | |
| EP4741379A1 (en) | Class of programmed cell death inhibitors, preparation method therefor and use thereof | |
| JP2013515766A (ja) | イマチニブジクロロ酢酸塩及びそれを含む抗癌剤組成物 | |
| JP6606806B2 (ja) | 重水素化キナゾリノン化合物及び該化合物を含む薬物組成物 | |
| US12486246B2 (en) | Replication protein A (RPA)-DNA interaction inhibitors | |
| Yuan et al. | Pioneering 4, 11-Dioxo-4, 11-dihydro-1 H-anthra [2, 3-d] imidazol-3-ium Compounds as Promising Survivin Inhibitors by Targeting ILF3/NF110 for Cancer Therapy | |
| CA2824028A1 (en) | Novel ureas for the treatment and prevention of cancer | |
| AU2018321287A1 (en) | Azole analogues and methods of use thereof | |
| EP3242881B1 (en) | Furoquinolinediones as inhibitors of tdp2 | |
| CN107513040A (zh) | 取代苯并嘧啶类化合物的制备及分子靶向肿瘤治疗药物的应用 | |
| WO2017181974A1 (zh) | 五元杂环类化合物及其制备方法、药物组合物和用途 | |
| CN107304203A (zh) | 五元杂环类化合物及其制备方法、药物组合物和用途 | |
| CN107459491A (zh) | 含1,2,3‑三氮唑结构的苯甲酰胺类化合物及其用途 | |
| EP3049386B1 (en) | Compounds useful in the treatment of neoplastic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220915 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241028 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241206 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241206 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241206 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250219 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250219 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250603 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250603 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251205 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251205 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260320 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260320 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20260628 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260716 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260716 |